
NYSEHealthcareMedical - Care Facilities
最新数据
US$21.21
+US$0.15 · +0.71%
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
前收盘价
US$21.21
+US$0.15 · +0.71%
盘前
US$21.46
+US$0.25 · +1.18%
10月13日 4:03 ET
盘中时间采用ET。市场数据可能有所延迟。
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
日内区间
当前US$21.21
52周区间
当前US$21.21
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
89
深度低估
情绪
48
多空交织
风险
29
中等风险
动量
43
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
日内区间
当前US$21.21
52周区间
当前US$21.21
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(EUR) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 196.28亿 EUR | 193.36亿 EUR | 194.54亿 EUR | 193.98亿 EUR | 176.19亿 EUR |
| 销货成本 | 145.99亿 EUR | 145.79亿 EUR | 145.29亿 EUR | 145.04亿 EUR | 128.46亿 EUR |
| 毛利 | 50.29亿 EUR | 47.57亿 EUR | 49.25亿 EUR | 48.94亿 EUR | 47.73亿 EUR |
| 研究与开发 | 1.58亿 EUR | 1.83亿 EUR | 2.32亿 EUR | 2.29亿 EUR | 2.21亿 EUR |
| 销售、一般及管理费用 | 30.33亿 EUR | 31.43亿 EUR | 31.96亿 EUR | 31.7亿 EUR | 27.73亿 EUR |
| 营业费用 | 32.02亿 EUR | 32.89亿 EUR | 35.56亿 EUR | 33.82亿 EUR | 29.21亿 EUR |
| 利息收入 | 6961.1万 EUR | 7157.5万 EUR | 8821.7万 EUR | 6766.3万 EUR | 7317万 EUR |
| 利息支出 | 3.84亿 EUR | 4.07亿 EUR | 4.25亿 EUR | 3.6亿 EUR | 3.54亿 EUR |
| 折旧和摊销 | 15亿 EUR | 17.42亿 EUR | 17.52亿 EUR | 18.38亿 EUR | 16.24亿 EUR |
| 营业利润 | 18.27亿 EUR | 14.67亿 EUR | 13.69亿 EUR | 15.12亿 EUR | 18.52亿 EUR |
| 净利润 | 9.78亿 EUR | 5.38亿 EUR | 4.99亿 EUR | 6.73亿 EUR | 9.69亿 EUR |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$23.67
上涨空间 11.60%年度分割调整后的每股现金分配。
US$0.815
2025年(完整年度)-2.3% 自从 2021
2026年(部分年度):US$0.8644
US$0.8338
2,021
US$0.7093
2,022
US$0.6181
2,023
US$0.6342
2,024
US$0.815
2,025
US$0.8644
2,026*
* 在现有股息历史记录中,该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年5月22日 | US$0.8644Annual | 2026年5月22日 | 2026年6月8日 |
股息 | 2025年5月23日 | US$0.815Annual | 2025年5月23日 | 2025年6月6日 |
股息 | 2024年5月17日 | US$0.6342Annual | 2024年5月20日 | 2024年6月3日 |
股息 | 2023年5月17日 | US$0.6181Annual | 2023年5月18日 | 2023年6月1日 |
股息 | 2022年5月13日 | US$0.7093Annual | 2022年5月16日 | 2022年5月27日 |
股息 | 2021年5月24日 | US$0.8338Annual | 2021年5月25日 | 2021年6月7日 |
除息 2026年5月22日
US$0.8644
Annual
2026年5月22日登记 · 支付日 2026年6月8日
除息 2025年5月23日
US$0.815
Annual
2025年5月23日登记 · 支付日 2025年6月6日
除息 2024年5月17日
US$0.6342
Annual
2024年5月20日登记 · 支付日 2024年6月3日
除息 2023年5月17日
US$0.6181
Annual
2023年5月18日登记 · 支付日 2023年6月1日
除息 2022年5月13日
US$0.7093
Annual
2022年5月16日登记 · 支付日 2022年5月27日
除息 2021年5月24日
US$0.8338
Annual
2021年5月25日登记 · 支付日 2021年6月7日
报告持有此股票敞口的交易所交易基金。
Pzena U.S. Large Cap Value ETFPZLV225.57万3.30%6940万 USD0.60%US$30.4598+0.39%
Avantis International Equity ETFAVDE124.5万0.01%192.24亿 USD0.23%US$89.58-0.24%
iShares Flexible Equity Active ETFBFLX109.32万0.05%21.85亿 USD0.40%US$26.0718-0.17%
ActivePassive International Equity ETFAPIE66.11万0.06%11.41亿 USD0.45%US$38.40-0.41%
ETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIV36.35万1.13%3209.03万 USD0.54%US$29.8734-0.08%
ETF Opportunities Trust - Cultivar ETFCVAR28.31万0.63%4503.71万 USD0.87%US$30.6578+0.41%
Dimensional - International Core Equity Market ETFDFAI7.46万0.00%177.82亿 USD0.18%US$41.27-0.17%
Dimensional - International Value ETFDFIV3.14万0.00%213.87亿 USD0.27%US$55.44+0.04%
Pzena U.S. Large Cap Value ETFPZLV
Avantis International Equity ETFAVDE
iShares Flexible Equity Active ETFBFLX
ActivePassive International Equity ETFAPIE
ETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIV
ETF Opportunities Trust - Cultivar ETFCVAR
Dimensional - International Core Equity Market ETFDFAI
Dimensional - International Value ETFDFIVAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。